Detail Information of Exogenous Modulation
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0112 Transporter Info | ||||
Gene Name | SLC16A8 | ||||
Transporter Name | Monocarboxylate transporter 3 | ||||
Gene ID | |||||
UniProt ID | |||||
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
---|---|---|---|---|---|
Chemical Compound |
|||||
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC16A8 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Benzo(a)pyrene |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene results in increased methylation of SLC16A8 exon | [6] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Benzo(a)pyrene results in increased methylation of SLC16A8 promoter | [6] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
dorsomorphin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC16A8 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
pirinixic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
pirinixic acid binds to and results in increased activity of PPARA protein which results in decreased expression of SLC16A8 mRNA | [7] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Valproic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valproic Acid results in increased methylation of SLC16A8 gene | [9] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Vorinostat |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased expression of SLC16A8 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Mycotoxins |
|||||
Aflatoxin B1 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aflatoxin B1 results in increased methylation of SLC16A8 polyA tail | [5] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Natural Product |
|||||
Resveratrol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Plant Extracts co-treated with Resveratrol results in decreased expression of SLC16A8 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Cisplatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cisplatin inhibits the expression of SLC16A8 | [1] | |||
Patented Pharmaceutical Agent |
|||||
GSK-J4 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
GSK-J4 inhibits the expression of SLC16A8 | [3] | |||
Herbicide |
|||||
Atrazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atrazine increases the expression of SLC16A8 | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.